voice activated technology

HNF Partners with True Reply, the Future of Data Collection: Voice Activated Technology (VAT)

by | Dec 8, 2018 | 0 comments

True Reply Logo

  • Accessible and innovative new platform allows for HNF to capture the patient’s experience with CMT in their own words
  • Respondents call into a toll free number where they are asked a series of questions
  • Data is then processed with Artificial Intelligence powered analytics to reveal telling insights
  • Pilot study was launched in 2017 at HNF’s Patient-Centered CMT/HNPP Pain Summit (funded by PCORI’s Eugene Washington Engagement Award #EAIN-7238) where patients were asked to use one word to describe their disease. PAIN was the #1 response
  • Internal Review Board (IRB) approved study through HNF’s patient registry, GRIN, captured 292 patient testimonies in their own voice and 27 of these testimonies were presented to the FDA during the Externally-led PFDD Meeting

true reply graphic

So go ahead and speak up.


Learn more on this topic

Related Blog Posts

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

HNF-WVU-NIOSH Study update:

We are pleased to update our readers on the progress of the WVU-NIOSH study, “A Bi-Directional Translational Model of Exercise Training in the Treatment of Charcot-Marie-Tooth Disease”

Dr. Robert Baloh Answers Our Questions About iPS Cell Research

Big news is happening on a cellular level at Cedars-Sinai Medical Center’s Regenerative Medicine Institute in Los Angeles, CA.  Robert H. Baloh, MD PhD, Director of Neuromuscular Medicine, in conjunction with Patrick D. Lyden, MD Neurology Dept. Chair, and Clive Svendsen, PhD, Institute Director, are studying disorders that start in nerve cells. 

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news